Abstract
BackgroundPrevious studies on the association of p53 codon 72 (Arg72Pro) polymorphism with hematological malignancies risk have produced conflicting results. The purpose of this meta-analysis is to define the effect of p53 Arg72Pro polymorphism on hematological malignancies risk.Methodology/Principal FindingsThrough searching PubMed databases (or hand searching) up to April 2012 using the following MeSH terms and keywords: “p53”, “codon 72” “polymorphism” and “leukemia”, or “lymphoma”, or “myeloma”, thirteen were identified as eligible articles in this meta-analysis for p53 Arg72Pro polymorphism (2,731 cases and 7, 356 controls), including nine studies on leukemia (1,266 cases and 4, 474 controls), three studies on lymphoma (1,359 cases and 2,652 controls), and one study on myeloma. The overall results suggested that p53 Arg72Pro polymorphism was not associated with hematological malignancies risk. In stratified analyses, significantly increased non-Hodgkin lymphomas risk was found in p53 Arg72Pro polymorphism heterozygote model (Arg/Pro vs. Arg/Arg: OR = 1.18, 95%CI: 1.02–1.35) and dominant model (Arg/Pro+Pro/Pro vs. Arg/Arg: OR = 1.18, 95%CI: 1.03–1.34), but no significant association was found between leukemia risk and p53 Arg72Pro polymorphism. Further studies showed no association between leukemia risk and p53 Arg72Pro polymorphism when stratified in subtypes of leukemias, ethnicities and sources of controls.Conclusions/SignificanceThis meta-analysis indicates that the p53 Arg72Pro polymorphism may contribute to susceptibility to non-Hodgkin lymphomas.
Highlights
Hematological malignancies derived from either of the two major blood cell lineages: myeloid and lymphoid cell lines, include leukemias, lymphomas, myeloma, myelodysplastic syndromes and myeloproliferative diseases
Our meta-analysis showed that significantly increased nonHodgkin lymphoma patients (NHL) risks were found in all subjects with p53 Arg72Pro polymorphism heterozygote and dominant model
No significant association was found between p53 Arg72Pro polymorphism and leukemia risk
Summary
Hematological malignancies derived from either of the two major blood cell lineages: myeloid and lymphoid cell lines, include leukemias, lymphomas, myeloma, myelodysplastic syndromes and myeloproliferative diseases. The etiology of hematological malignancies appears to be multifactorial, including the inherited mutations in DNA, and exposure to ionizing radiation, or to chemicals like benzene or cytotoxic therapy Exposure to these carcinogens may cause DNA damage at the level of hematopoietic progenitors and develop hematological malignancies; the majority of cases likely involve genetic variations with a high-risk phenotype [3]. These gene-gene interactions, as well as their interplay with lifestyle-related factors and environmental agents, may be major determinants in hematological malignancy susceptibility [4]. The purpose of this meta-analysis is to define the effect of p53 Arg72Pro polymorphism on hematological malignancies risk
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
